ACP does not support QPP measure 447: "Chlamydia Screening and Follow-Up."
Implementation could promote overuse of chlamydia screening in patients prescribed hormonal contraceptive therapy for acne, premenstrual dysphoric disorder, dysmenorrhea, etc. Furthermore, specifications define “sexually active” through claims/encounter based data and pharmacy data. Pharmacy data may inaccurately identify sexually active patients in cases where hormonal therapy is prescribed for acne and dysmenorrhea management. Also, denominator specifications do not capture women who are prescribed implantable devices for contraception management.